Drugs that contain Glucagon
1. Baqsimi patents expiration
BAQSIMI's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6938798 | AMPHASTAR PHARMS INC | Fluid or powdery product dispensing device |
Jan, 2022
(2 years ago) | |
| US10213487 | AMPHASTAR PHARMS INC | Nasal powder formulation for treatment of hypoglycemia |
Feb, 2036
(11 years from now) | |
| US10894133 | AMPHASTAR PHARMS INC | Device for dispensing a fluid product |
Jan, 2038
(13 years from now) | |
| US10765602 | AMPHASTAR PHARMS INC | Medication delivery systems and methods |
Sep, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 24, 2022 |
Market Authorisation Date: 24 July, 2019
Treatment: Treatment of severe hypoglycemia in patients with diabetes
Dosage: POWDER;NASAL
More Information on Dosage
BAQSIMI family patents
2. Gvoke Hypopen patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9649364 | XERIS | Methods for producing stable therapeutic formulations in aprotic polar solvents |
Apr, 2036
(11 years from now) | |
| US11590205 | XERIS | Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents |
Apr, 2036
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 10, 2022 |
Market Authorisation Date: 10 September, 2019
Treatment: Treatment of severe hypoglycemia
Dosage: SOLUTION;SUBCUTANEOUS
More Information on Dosage
GVOKE HYPOPEN family patents
3. Gvoke Kit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11590205 | XERIS | Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents |
Apr, 2036
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 10, 2022 |
Market Authorisation Date: 10 September, 2019
Treatment: Treatment of severe hypoglycemia
Dosage: SOLUTION;SUBCUTANEOUS
More Information on Dosage
GVOKE KIT family patents
4. Gvoke Pfs patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11590205 | XERIS | Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents |
Apr, 2036
(11 years from now) | |
| US9649364 | XERIS | Methods for producing stable therapeutic formulations in aprotic polar solvents |
Apr, 2036
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 10, 2022 |
Market Authorisation Date: 10 September, 2019
Treatment: Treatment of severe hypoglycemia
Dosage: SOLUTION;SUBCUTANEOUS
More Information on Dosage
GVOKE PFS family patents